Skip to main content
Erschienen in: Annals of Nuclear Medicine 2/2023

27.11.2022 | Original Article

Glucose metabolic heterogeneity correlates with pathological features and improves survival stratification of resectable lung adenocarcinoma

verfasst von: Yu-Hung Chen, Yen-Chang Chen, Kun-Han Lue, Sung-Chao Chu, Bee-Song Chang, Ling-Yi Wang, Ming-Hsun Li, Chih-Bin Lin

Erschienen in: Annals of Nuclear Medicine | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

We investigated whether glycolytic heterogeneity correlated with histopathology, and further stratified the survival outcomes pertaining to resectable lung adenocarcinoma.

Methods

We retrospectively analyzed the 18F-fluorodeoxyglucose positron emission tomography-derived entropy and histopathology from 128 patients who had undergone curative surgery for lung adenocarcinoma. Disease-free survival (DFS) and overall survival (OS) were analyzed using univariate and multivariate Cox regression models. Independent predictors were used to construct survival prediction models.

Results

Entropy significantly correlated with histopathology, including tumor grades, lympho-vascular invasion, and visceral pleural invasion. Furthermore, entropy was an independent predictor of unfavorable DFS (p = 0.031) and OS (p = 0.004), while pathological nodal metastasis independently predicted DFS (p = 0.009). Our entropy-based models outperformed the traditional staging system (c-index = 0.694 versus 0.636, p = 0.010 for DFS; c-index = 0.704 versus 0.630, p = 0.233 for OS). The models provided further survival stratification in subgroups comprising different tumor grades (DFS: HR = 2.065, 1.315, and 1.408 for grade 1–3, p = 0.004, 0.001, and 0.039, respectively; OS: HR = 25.557, 6.484, and 2.570, for grade 1–3, p = 0.006, < 0.001, and = 0.224, respectively).

Conclusion

The glycolytic heterogeneity portrayed by entropy is associated with aggressive histopathological characteristics. The proposed entropy-based models may provide more sophisticated survival stratification in addition to histopathology and may enable personalized treatment strategies for resectable lung cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ruffini E, Rena O, Oliaro A, Filosso PL, Bongiovanni M, Arslanian A, et al. Lung tumors with mixed histologic pattern. Clinico-pathologic characteristics and prognostic significance. Eur J Cardiothorac Surg. 2002;22:701–7.CrossRef Ruffini E, Rena O, Oliaro A, Filosso PL, Bongiovanni M, Arslanian A, et al. Lung tumors with mixed histologic pattern. Clinico-pathologic characteristics and prognostic significance. Eur J Cardiothorac Surg. 2002;22:701–7.CrossRef
2.
Zurück zum Zitat Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85:8.CrossRef Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85:8.CrossRef
3.
Zurück zum Zitat Chen YH, Wang TF, Chu SC, Lin CB, Wang LY, Lue KH, et al. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma. PLoS One. 2020;15: e0244502.CrossRef Chen YH, Wang TF, Chu SC, Lin CB, Wang LY, Lue KH, et al. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma. PLoS One. 2020;15: e0244502.CrossRef
4.
Zurück zum Zitat Kim HC, Ji W, Lee JC, Kim HR, Song SY, Choi CM, et al. Prognostic factor and clinical outcome in stage III non-small cell lung cancer: a study based on real-world clinical data in the korean population. Cancer Res Treat. 2021;53:1033–41.CrossRef Kim HC, Ji W, Lee JC, Kim HR, Song SY, Choi CM, et al. Prognostic factor and clinical outcome in stage III non-small cell lung cancer: a study based on real-world clinical data in the korean population. Cancer Res Treat. 2021;53:1033–41.CrossRef
5.
Zurück zum Zitat Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81:371–6.CrossRef Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81:371–6.CrossRef
6.
Zurück zum Zitat Sakurai H, Asamura H, Miyaoka E, Yoshino I, Fujii Y, Nakanishi Y, et al. Differences in the prognosis of resected lung adenocarcinoma according to the histological subtype: a retrospective analysis of Japanese lung cancer registry data. Eur J Cardiothorac Surg. 2014;45:100–7.CrossRef Sakurai H, Asamura H, Miyaoka E, Yoshino I, Fujii Y, Nakanishi Y, et al. Differences in the prognosis of resected lung adenocarcinoma according to the histological subtype: a retrospective analysis of Japanese lung cancer registry data. Eur J Cardiothorac Surg. 2014;45:100–7.CrossRef
7.
Zurück zum Zitat Chen T, Luo J, Gu H, Gu Y, Huang Q, Wang Y, et al. Impact of solid minor histologic subtype in postsurgical prognosis of stage I lung adenocarcinoma. Ann Thorac Surg. 2018;105:302–8.CrossRef Chen T, Luo J, Gu H, Gu Y, Huang Q, Wang Y, et al. Impact of solid minor histologic subtype in postsurgical prognosis of stage I lung adenocarcinoma. Ann Thorac Surg. 2018;105:302–8.CrossRef
8.
Zurück zum Zitat Moreira AL, Ocampo PSS, Xia Y, Zhong H, Russell PA, Minami Y, et al. A grading system for invasive pulmonary adenocarcinoma: a proposal from the international association for the study of lung cancer pathology committee. J Thorac Oncol. 2020;15:1599–610.CrossRef Moreira AL, Ocampo PSS, Xia Y, Zhong H, Russell PA, Minami Y, et al. A grading system for invasive pulmonary adenocarcinoma: a proposal from the international association for the study of lung cancer pathology committee. J Thorac Oncol. 2020;15:1599–610.CrossRef
9.
Zurück zum Zitat Schuchert MJ, Normolle DP, Awais O, Pennathur A, Wilson DO, Luketich JD, et al. Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer. Lung Cancer. 2019;128:145–51.CrossRef Schuchert MJ, Normolle DP, Awais O, Pennathur A, Wilson DO, Luketich JD, et al. Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer. Lung Cancer. 2019;128:145–51.CrossRef
10.
Zurück zum Zitat Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24:653–64.CrossRef Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24:653–64.CrossRef
11.
Zurück zum Zitat Hou Y, Song W, Chen M, Zhang J, Luo Q, Um SW, et al. The presence of lepidic and micropapillary/solid pathological patterns as minor components has prognostic value in patients with intermediate-grade invasive lung adenocarcinoma. Transl Lung Cancer Res. 2022;11:64–74.CrossRef Hou Y, Song W, Chen M, Zhang J, Luo Q, Um SW, et al. The presence of lepidic and micropapillary/solid pathological patterns as minor components has prognostic value in patients with intermediate-grade invasive lung adenocarcinoma. Transl Lung Cancer Res. 2022;11:64–74.CrossRef
12.
Zurück zum Zitat Chen YH, Chu SC, Wang LY, Wang TF, Lue KH, Lin CB, et al. Prognostic value of combing primary tumor and nodal glycolytic-volumetric parameters of (18)F-FDG PET in patients with non-small cell lung cancer and regional lymph node metastasis. Diagnostics (Basel). 2021;11:1065.CrossRef Chen YH, Chu SC, Wang LY, Wang TF, Lue KH, Lin CB, et al. Prognostic value of combing primary tumor and nodal glycolytic-volumetric parameters of (18)F-FDG PET in patients with non-small cell lung cancer and regional lymph node metastasis. Diagnostics (Basel). 2021;11:1065.CrossRef
13.
Zurück zum Zitat Aragaki M, Kato T, Fujiwara-Kuroda A, Hida Y, Kaga K, Wakasa S. Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study. J Cardiothorac Surg. 2020;15:229.CrossRef Aragaki M, Kato T, Fujiwara-Kuroda A, Hida Y, Kaga K, Wakasa S. Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study. J Cardiothorac Surg. 2020;15:229.CrossRef
14.
Zurück zum Zitat Pellegrino S, Fonti R, Pulcrano A, Del Vecchio S. PET-based volumetric biomarkers for risk stratification of non-small cell lung cancer patients. Diagnostics (Basel). 2021;11:210.CrossRef Pellegrino S, Fonti R, Pulcrano A, Del Vecchio S. PET-based volumetric biomarkers for risk stratification of non-small cell lung cancer patients. Diagnostics (Basel). 2021;11:210.CrossRef
15.
Zurück zum Zitat Sun XY, Chen TX, Chang C, Teng HH, Xie C, Ruan MM, et al. SUVmax of (18)FDG PET/CT predicts histological grade of lung adenocarcinoma. Acad Radiol. 2021;28:49–57.CrossRef Sun XY, Chen TX, Chang C, Teng HH, Xie C, Ruan MM, et al. SUVmax of (18)FDG PET/CT predicts histological grade of lung adenocarcinoma. Acad Radiol. 2021;28:49–57.CrossRef
16.
Zurück zum Zitat Kim KH, Ryu SY, Lee HY, Choi JY, Kwon OJ, Kim HK, et al. Evaluating the tumor biology of lung adenocarcinoma: a multimodal analysis. Medicine. 2019;98: e16313.CrossRef Kim KH, Ryu SY, Lee HY, Choi JY, Kwon OJ, Kim HK, et al. Evaluating the tumor biology of lung adenocarcinoma: a multimodal analysis. Medicine. 2019;98: e16313.CrossRef
17.
Zurück zum Zitat Yu M, Chen S, Hong W, Gu Y, Huang B, Lin Y, et al. Prognostic role of glycolysis for cancer outcome: evidence from 86 studies. J Cancer Res Clin Oncol. 2019;145:967–99.CrossRef Yu M, Chen S, Hong W, Gu Y, Huang B, Lin Y, et al. Prognostic role of glycolysis for cancer outcome: evidence from 86 studies. J Cancer Res Clin Oncol. 2019;145:967–99.CrossRef
18.
Zurück zum Zitat Kim G, Kim J, Cha H, Park WY, Ahn JS, Ahn MJ, et al. Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. Sci Rep. 2020;10:13231.CrossRef Kim G, Kim J, Cha H, Park WY, Ahn JS, Ahn MJ, et al. Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. Sci Rep. 2020;10:13231.CrossRef
19.
Zurück zum Zitat Lue KH, Huang CH, Hsieh TC, Liu SH, Wu YF, Chen YH. Systemic inflammation index and tumor glycolytic heterogeneity help risk stratify patients with advanced epidermal growth factor receptor-mutated lung adenocarcinoma treated with tyrosine kinase inhibitor therapy. Cancers. 2022;14:309.CrossRef Lue KH, Huang CH, Hsieh TC, Liu SH, Wu YF, Chen YH. Systemic inflammation index and tumor glycolytic heterogeneity help risk stratify patients with advanced epidermal growth factor receptor-mutated lung adenocarcinoma treated with tyrosine kinase inhibitor therapy. Cancers. 2022;14:309.CrossRef
20.
Zurück zum Zitat Ouyang ML, Xia HW, Xu MM, Lin J, Wang LL, Zheng XW, et al. Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1–2N0M0 lung cancer patients staged by PET/CT. Ann Nucl Med. 2019;33:671–80.CrossRef Ouyang ML, Xia HW, Xu MM, Lin J, Wang LL, Zheng XW, et al. Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1–2N0M0 lung cancer patients staged by PET/CT. Ann Nucl Med. 2019;33:671–80.CrossRef
21.
Zurück zum Zitat Pyka T, Bundschuh RA, Andratschke N, Mayer B, Specht HM, Papp L, et al. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. Radiat Oncol. 2015;10:100.CrossRef Pyka T, Bundschuh RA, Andratschke N, Mayer B, Specht HM, Papp L, et al. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. Radiat Oncol. 2015;10:100.CrossRef
22.
Zurück zum Zitat Nakanishi K, Nakamura S, Sugiyama T, Kadomatsu Y, Ueno H, Goto M, et al. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer. BMC Cancer. 2021;21:983.CrossRef Nakanishi K, Nakamura S, Sugiyama T, Kadomatsu Y, Ueno H, Goto M, et al. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer. BMC Cancer. 2021;21:983.CrossRef
23.
Zurück zum Zitat Lue KH, Chu SC, Wang LY, Chen YC, Li MH, Chang BS, et al. Tumor glycolytic heterogeneity improves detection of regional nodal metastasis in patients with lung adenocarcinoma. Ann Nucl Med. 2022;36:256–66.CrossRef Lue KH, Chu SC, Wang LY, Chen YC, Li MH, Chang BS, et al. Tumor glycolytic heterogeneity improves detection of regional nodal metastasis in patients with lung adenocarcinoma. Ann Nucl Med. 2022;36:256–66.CrossRef
24.
Zurück zum Zitat Sato R, Imamura K, Semba T, Tomita Y, Saeki S, Ikeda K, et al. TGFbeta signaling activated by cancer-associated fibroblasts determines the histological signature of lung adenocarcinoma. Cancer Res. 2021;81:4751–65.CrossRef Sato R, Imamura K, Semba T, Tomita Y, Saeki S, Ikeda K, et al. TGFbeta signaling activated by cancer-associated fibroblasts determines the histological signature of lung adenocarcinoma. Cancer Res. 2021;81:4751–65.CrossRef
25.
Zurück zum Zitat Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the tnm stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRef Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the tnm stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRef
26.
Zurück zum Zitat Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRef Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRef
27.
Zurück zum Zitat van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–7.CrossRef van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–7.CrossRef
28.
Zurück zum Zitat Zwanenburg A, Vallieres M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328–38.CrossRef Zwanenburg A, Vallieres M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328–38.CrossRef
29.
Zurück zum Zitat Oliver JA, Budzevich M, Zhang GG, Dilling TJ, Latifi K, Moros EG. Variability of image features computed from conventional and respiratory-gated PET/CT images of lung cancer. Transl Oncol. 2015;8:524–34.CrossRef Oliver JA, Budzevich M, Zhang GG, Dilling TJ, Latifi K, Moros EG. Variability of image features computed from conventional and respiratory-gated PET/CT images of lung cancer. Transl Oncol. 2015;8:524–34.CrossRef
30.
Zurück zum Zitat Desseroit MC, Tixier F, Weber WA, Siegel BA, Cheze Le Rest C, Visvikis D, et al. Reliability of PET/CT shape and heterogeneity features in functional and morphologic components of non-small cell lung cancer tumors: a repeatability analysis in a prospective multicenter cohort. J Nucl Med. 2017;58:406–11.CrossRef Desseroit MC, Tixier F, Weber WA, Siegel BA, Cheze Le Rest C, Visvikis D, et al. Reliability of PET/CT shape and heterogeneity features in functional and morphologic components of non-small cell lung cancer tumors: a repeatability analysis in a prospective multicenter cohort. J Nucl Med. 2017;58:406–11.CrossRef
31.
Zurück zum Zitat Traverso A, Wee L, Dekker A, Gillies R. Repeatability and reproducibility of radiomic features: a systematic review. Int J Radiat Oncol Biol Phys. 2018;102:1143–58.CrossRef Traverso A, Wee L, Dekker A, Gillies R. Repeatability and reproducibility of radiomic features: a systematic review. Int J Radiat Oncol Biol Phys. 2018;102:1143–58.CrossRef
32.
Zurück zum Zitat Xu H, Lv W, Zhang H, Ma J, Zhao P, Lu L. Evaluation and optimization of radiomics features stability to respiratory motion in (18) F-FDG 3D PET imaging. Med Phys. 2021;48:5165–78.CrossRef Xu H, Lv W, Zhang H, Ma J, Zhao P, Lu L. Evaluation and optimization of radiomics features stability to respiratory motion in (18) F-FDG 3D PET imaging. Med Phys. 2021;48:5165–78.CrossRef
33.
Zurück zum Zitat Polley MC, Dignam JJ. Statistical considerations in the evaluation of continuous biomarkers. J Nucl Med. 2021;62:605–11.CrossRef Polley MC, Dignam JJ. Statistical considerations in the evaluation of continuous biomarkers. J Nucl Med. 2021;62:605–11.CrossRef
34.
Zurück zum Zitat Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRef Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRef
35.
Zurück zum Zitat Kang L, Chen W, Petrick NA, Gallas BD. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med. 2015;34:685–703.CrossRef Kang L, Chen W, Petrick NA, Gallas BD. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med. 2015;34:685–703.CrossRef
36.
Zurück zum Zitat Ujiie H, Kadota K, Chaft JE, Buitrago D, Sima CS, Lee MC, et al. Solid predominant histologic subtype in resected stage I lung adenocarcinoma is an independent predictor of early, extrathoracic, multisite recurrence and of poor postrecurrence survival. J Clin Oncol. 2015;33:2877–84.CrossRef Ujiie H, Kadota K, Chaft JE, Buitrago D, Sima CS, Lee MC, et al. Solid predominant histologic subtype in resected stage I lung adenocarcinoma is an independent predictor of early, extrathoracic, multisite recurrence and of poor postrecurrence survival. J Clin Oncol. 2015;33:2877–84.CrossRef
37.
Zurück zum Zitat Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85.CrossRef Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85.CrossRef
38.
Zurück zum Zitat Turajlic S, Swanton C. Metastasis as an evolutionary process. Science. 2016;352:169–75.CrossRef Turajlic S, Swanton C. Metastasis as an evolutionary process. Science. 2016;352:169–75.CrossRef
39.
Zurück zum Zitat Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 2017;15:133.CrossRef Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 2017;15:133.CrossRef
40.
Zurück zum Zitat Jiangdian S, Di D, Yanqi H, Yali Z, Zaiyi L, Jie T. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy. Conf Proc IEEE Eng Med Biol Soc. 2016;2016:1268–71. Jiangdian S, Di D, Yanqi H, Yali Z, Zaiyi L, Jie T. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy. Conf Proc IEEE Eng Med Biol Soc. 2016;2016:1268–71.
41.
Zurück zum Zitat McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613–28.CrossRef McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613–28.CrossRef
42.
Zurück zum Zitat Moon SH, Kim J, Joung JG, Cha H, Park WY, Ahn JS, et al. Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. Eur J Nucl Med Mol Imaging. 2019;46:446–54.CrossRef Moon SH, Kim J, Joung JG, Cha H, Park WY, Ahn JS, et al. Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. Eur J Nucl Med Mol Imaging. 2019;46:446–54.CrossRef
43.
Zurück zum Zitat Sereno M, He Z, Smith CR, Baena J, Das M, Hastings RK, et al. Inclusion of multiple high-risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma. Histopathology. 2021;78:838–48.CrossRef Sereno M, He Z, Smith CR, Baena J, Das M, Hastings RK, et al. Inclusion of multiple high-risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma. Histopathology. 2021;78:838–48.CrossRef
44.
Zurück zum Zitat Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol. 2022;40:546–55.CrossRef Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol. 2022;40:546–55.CrossRef
45.
Zurück zum Zitat Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344–57.CrossRef Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344–57.CrossRef
46.
Zurück zum Zitat Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in lung cancer: current landscape and future directions. Front Immunol. 2022;13: 823618.CrossRef Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in lung cancer: current landscape and future directions. Front Immunol. 2022;13: 823618.CrossRef
47.
Zurück zum Zitat Melosky B, Cheema P, Juergens RA, Leighl NB, Liu G, Wheatley-Price P, et al. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Ther Adv Med Oncol. 2021;13:17588359211056306.CrossRef Melosky B, Cheema P, Juergens RA, Leighl NB, Liu G, Wheatley-Price P, et al. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Ther Adv Med Oncol. 2021;13:17588359211056306.CrossRef
48.
Zurück zum Zitat Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, et al. Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol. 2022;17:423–33.CrossRef Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, et al. Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol. 2022;17:423–33.CrossRef
49.
Zurück zum Zitat Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KGM. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol. 2003;56:441–7.CrossRef Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KGM. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol. 2003;56:441–7.CrossRef
50.
Zurück zum Zitat Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35:214–26.CrossRef Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35:214–26.CrossRef
Metadaten
Titel
Glucose metabolic heterogeneity correlates with pathological features and improves survival stratification of resectable lung adenocarcinoma
verfasst von
Yu-Hung Chen
Yen-Chang Chen
Kun-Han Lue
Sung-Chao Chu
Bee-Song Chang
Ling-Yi Wang
Ming-Hsun Li
Chih-Bin Lin
Publikationsdatum
27.11.2022
Verlag
Springer Nature Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 2/2023
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-022-01811-y

Weitere Artikel der Ausgabe 2/2023

Annals of Nuclear Medicine 2/2023 Zur Ausgabe

Acknowledgment to Reviewers

Acknowledgements to Reviewers